Newsroom

Geistlich announces the dramatic expansion of their allograft portfolio – vallos® sets the pace for regeneration

Geistlich Pharma North America, Inc. acquires Lynch Biologics, LLC, a biologics and tissue engineering company

Geistlich unveils vallos™ – a new demineralized allograft that sets the pace for regeneration